Related Experiment Video
Updated: May 23, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
The Prostate cancer Research International: Active Surveillance study
Chris H Bangma1, Meelan Bul, Monique Roobol
1Department of Urology, Erasmus MC, Rotterdam, The Netherlands. h.j.vanalphen@erasmusmc.nl
Current Opinion in Urology
|March 29, 2012
Summary
The Prostate cancer Research International: Active Surveillance (PRIAS) study tracks over 2000 men with low-risk prostate cancer globally. About 27% of men required treatment changes, with 22% switching to active therapy.
Area of Science:
- Urology
- Oncology
- Clinical Research
Background:
- Active surveillance is a management strategy for low-risk prostate cancer.
- Worldwide research is needed to refine active surveillance protocols.
- The Prostate cancer Research International: Active Surveillance (PRIAS) study addresses this need.
Purpose of the Study:
- To provide an update on the PRIAS study's activities and findings.
- To discuss current challenges and research questions in prostate cancer active surveillance.
- To highlight the global reach and methodology of the PRIAS study.
Main Methods:
- Utilized recent data from the PRIAS study.
- Incorporated a PubMed-based literature review from the past three years.
- Employed an electronic, web-based decision tool for physician access and data management.
Main Results:
- The PRIAS study has enrolled over 2000 men from 100+ centers in 17 countries since December 2006.
- Risk reclassification occurred in 27% of biopsied participants during follow-up.
- Active therapy was initiated in 22% of the total cohort.
Conclusions:
- The PRIAS study is a significant, growing global registry for active surveillance in low-risk prostate cancer.
- The study's infrastructure supports standardized inclusion and monitoring worldwide.
- Findings indicate a notable rate of risk reclassification and transition to active therapy within the monitored cohort.
